Transplantation outcomes: univariate analysis
| . | 2 years . | ||||
|---|---|---|---|---|---|
| Relapse . | NRM . | LFS . | OS . | GRFS . | |
| De novo AML | 46.3% (42-50.4) | 23.8% (20.3-27.4) | 30% (26.1-33.9) | 33.5% (29.4-37.6) | 23.8% (20.3-27.6) |
| sAML | 28.8% (20.9-37.1) | 38.7% (30-47.3) | 32.5% (24.3-41) | 34.4% (25.9-43.1) | 25% (17.6-33.1) |
| P value | .001 | .001 | .58 | .35 | .49 |
| . | 2 years . | ||||
|---|---|---|---|---|---|
| Relapse . | NRM . | LFS . | OS . | GRFS . | |
| De novo AML | 46.3% (42-50.4) | 23.8% (20.3-27.4) | 30% (26.1-33.9) | 33.5% (29.4-37.6) | 23.8% (20.3-27.6) |
| sAML | 28.8% (20.9-37.1) | 38.7% (30-47.3) | 32.5% (24.3-41) | 34.4% (25.9-43.1) | 25% (17.6-33.1) |
| P value | .001 | .001 | .58 | .35 | .49 |
| . | 180 days . | 2 years . | ||
|---|---|---|---|---|
| aGVHD grade 2-4 . | aGVHD grade 3-4 . | cGVHD . | Ext. cGVHD . | |
| De novo AML | 26.9% (23.3-30.6) | 10.4% (8-13.1) | 20.7% (17.3-24.3) | 10.3% (7.9-13.1) |
| sAML | 20% (13.5-27.4) | 8.9% (4.7-14.7) | 25.3% (17.7-33.5) | 12.5% (7.2-19.4) |
| P value | .12 | .61 | .27 | .46 |
| . | 180 days . | 2 years . | ||
|---|---|---|---|---|
| aGVHD grade 2-4 . | aGVHD grade 3-4 . | cGVHD . | Ext. cGVHD . | |
| De novo AML | 26.9% (23.3-30.6) | 10.4% (8-13.1) | 20.7% (17.3-24.3) | 10.3% (7.9-13.1) |
| sAML | 20% (13.5-27.4) | 8.9% (4.7-14.7) | 25.3% (17.7-33.5) | 12.5% (7.2-19.4) |
| P value | .12 | .61 | .27 | .46 |
Ext, extensive.